{"id":"https://openalex.org/W2148036720","doi":"https://doi.org/10.1016/j.bbmt.2013.12.021","title":"Risk Factors for Graft Failure and Survival after Reduced Intensity (RIC) Conditioning Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelofibrosis","display_name":"Risk Factors for Graft Failure and Survival after Reduced Intensity (RIC) Conditioning Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelofibrosis","publication_year":2014,"publication_date":"2014-02-01","ids":{"openalex":"https://openalex.org/W2148036720","doi":"https://doi.org/10.1016/j.bbmt.2013.12.021","mag":"2148036720"},"language":"en","primary_location":{"id":"doi:10.1016/j.bbmt.2013.12.021","doi":"https://doi.org/10.1016/j.bbmt.2013.12.021","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bbmt.2013.12.021","pdf_url":null,"source":{"id":"https://openalex.org/S59987174","display_name":"Transplantation and Cellular Therapy","issn_l":"1083-8791","issn":["1083-8791","1523-6536","2666-6367"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biology of Blood and Marrow Transplantation","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.bbmt.2013.12.021","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060510354","display_name":"Brett E. Glotzbecker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brett Glotzbecker","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045479163","display_name":"Haesook T. Kim","orcid":"https://orcid.org/0000-0003-4889-6849","observed_orcids":["https://orcid.org/0000-0003-4889-6849"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haesook T. Kim","raw_affiliation_strings":["2Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029278364","display_name":"Corey S. Cutler","orcid":"https://orcid.org/0000-0001-8728-4314","observed_orcids":["https://orcid.org/0000-0001-8728-4314"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corey S. Cutler","raw_affiliation_strings":["3Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029390145","display_name":"John Koreth","orcid":"https://orcid.org/0000-0002-7428-1330","observed_orcids":["https://orcid.org/0000-0002-7428-1330"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Koreth","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001407163","display_name":"Sarah Nikiforow","orcid":"https://orcid.org/0009-0001-2711-5575","observed_orcids":["https://orcid.org/0009-0001-2711-5575"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Nikiforow","raw_affiliation_strings":["3Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054037976","display_name":"Joseph H. Antin","orcid":"https://orcid.org/0000-0003-4627-1714","observed_orcids":["https://orcid.org/0000-0003-4627-1714"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph H. Antin","raw_affiliation_strings":["4Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068050082","display_name":"Robert J. Soiffer","orcid":"https://orcid.org/0000-0002-5810-1192","observed_orcids":["https://orcid.org/0000-0002-5810-1192"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert J. Soiffer","raw_affiliation_strings":["3Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074589634","display_name":"Edwin Pascal Alyea","orcid":"https://orcid.org/0000-0002-1885-8430","observed_orcids":["https://orcid.org/0000-0002-1885-8430"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin P. Alyea","raw_affiliation_strings":["1Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031812464","display_name":"Vincent T. Ho","orcid":"https://orcid.org/0000-0001-6839-3996","observed_orcids":["https://orcid.org/0000-0001-6839-3996"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vincent T. Ho","raw_affiliation_strings":["4Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":3650,"currency":"USD","value_usd":3650},"apc_paid":{"value":3650,"currency":"USD","value_usd":3650},"fwci":0.1563,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.53502151,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"20","issue":"2","first_page":"S34","last_page":"S34"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.8310999870300293,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.8310999870300293,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.15690000355243683,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9490000009536743},{"id":"https://openalex.org/keywords/reduced-intensity-conditioning","display_name":"reduced-intensity conditioning","score":0.9909999966621399},{"id":"https://openalex.org/keywords/allogeneic-hematopoietic-stem-cell-transplantation","display_name":"allogeneic hematopoietic stem cell transplantation","score":0.9869999885559082},{"id":"https://openalex.org/keywords/graft-failure","display_name":"graft failure","score":0.9660000205039978},{"id":"https://openalex.org/keywords/primary-graft-failure","display_name":"primary graft failure","score":0.875},{"id":"https://openalex.org/keywords/risk-factors","display_name":"risk factors","score":0.656000018119812},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.6430000066757202},{"id":"https://openalex.org/keywords/graft-versus-host-disease","display_name":"graft-versus-host disease","score":0.5899999737739563}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.961503267288208},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.8480152487754822},{"id":"https://openalex.org/C2780611847","wikidata":"https://www.wikidata.org/wiki/Q348922","display_name":"Busulfan","level":4,"score":0.7341191172599792},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.614819347858429},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.584862232208252},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.56996089220047},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5472415089607239},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.5024340152740479},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4237891435623169},{"id":"https://openalex.org/C2777408962","wikidata":"https://www.wikidata.org/wiki/Q1128050","display_name":"Hematopoietic stem cell transplantation","level":3,"score":0.37781617045402527},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.32505443692207336},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2548174262046814},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.2122216522693634},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.14319342374801636}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.bbmt.2013.12.021","doi":"https://doi.org/10.1016/j.bbmt.2013.12.021","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bbmt.2013.12.021","pdf_url":null,"source":{"id":"https://openalex.org/S59987174","display_name":"Transplantation and Cellular Therapy","issn_l":"1083-8791","issn":["1083-8791","1523-6536","2666-6367"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biology of Blood and Marrow Transplantation","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.bbmt.2013.12.021","doi":"https://doi.org/10.1016/j.bbmt.2013.12.021","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bbmt.2013.12.021","pdf_url":null,"source":{"id":"https://openalex.org/S59987174","display_name":"Transplantation and Cellular Therapy","issn_l":"1083-8791","issn":["1083-8791","1523-6536","2666-6367"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biology of Blood and Marrow Transplantation","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1064388514","https://openalex.org/W2108447738","https://openalex.org/W2972452355","https://openalex.org/W2426396078","https://openalex.org/W1972610696","https://openalex.org/W4283652707","https://openalex.org/W3024475394","https://openalex.org/W2562990393","https://openalex.org/W4310567296","https://openalex.org/W2331328319"],"abstract_inverted_index":{"Reduced":[0],"intensity":[1],"conditioning":[2],"(RIC)":[3],"HSCT":[4,52],"is":[5,16],"a":[6,17,42,49],"potentially":[7],"curative":[8],"therapy":[9],"for":[10,30,53,87],"Myelofibrosis":[11],"(MF),":[12],"but":[13],"graft":[14,31,72],"failure":[15,32,73],"major":[18],"cause":[19],"of":[20,45],"treatment":[21],"failure.":[22],"We":[23,40],"evaluated":[24],"the":[25,78],"outcomes":[26],"and":[27,33,60,67],"risk":[28],"factors":[29],"survival":[34],"in":[35],"patients":[36,47],"undergoing":[37],"RIC":[38,51],"HSCT.":[39],"performed":[41],"retrospective":[43],"review":[44],"all":[46],"receiving":[48],"first":[50],"MF":[54],"at":[55],"Dana":[56],"Farber":[57],"Cancer":[58],"Institute/Brigham":[59],"Women's":[61],"Hospital":[62],"between":[63],"January":[64],"1,":[65],"2000":[66],"December":[68],"31,":[69],"2012.":[70],"Primary":[71],"(PGF)":[74],"was":[75],"defined":[76],"as":[77],"inability":[79],"to":[80],"achieve":[81],"an":[82],"ANC":[83],"greater":[84],"than":[85],"0.5x109/L":[86],"three":[88],"consecutive":[89],"days.":[90]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}